<abstract><sec><title>Objectives</title><p>Administering outpatient parenteral antimicrobial therapy in the community setting (CoPAT) is becoming more common with the increasing emphasis on controlling costs. However, few controlled trials have evaluated this treatment modality.</p></sec><sec sec-type="methods"><title>Methods</title><p>Using data from a recent randomized trial comparing daptomycin with standard therapy (semi-synthetic penicillin or vancomycin, each with initial low-dose gentamicin) for <italic>Staphylococcus aureus</italic> bacteraemia and infective endocarditis (SAB/IE), patient characteristics and outcomes were evaluated. Patients receiving their full course of therapy in the hospital setting were compared with those who received some portion outside of the hospital (CoPAT).</p></sec><sec><title>Results</title><p>Among the 200 patients, 51.5% received CoPAT. These patients were generally younger (median age 50 versus 54 years, <italic>P</italic> = 0.028). In the CoPAT group, there tended to be fewer patients with endocardial involvement (8.7% versus 18.6%, <italic>P</italic> = 0.061) and pre-existing valvular heart disease (7.8% versus 15.5%, <italic>P</italic> = 0.120). CoPAT patients received longer therapy courses (mean 25.4 versus 13.5 days, <italic>P</italic> &#x0003c; 0.001) and had higher rates of therapy completion (90.3% versus 45.4%, <italic>P</italic> &#x0003c; 0.001) and clinical success (86.4% versus 55.7%, <italic>P</italic> &#x0003c; 0.001). Persisting or relapsing <italic>S</italic>. <italic>aureus</italic> was less frequent in the CoPAT group (3.9% versus 15.5%, <italic>P</italic> = 0.007) and there were fewer deaths (3.9% versus 18.6%, <italic>P</italic> = 0.001) 6 weeks after the end of therapy. Hospital readmission occurred for 18 of the 103 (17.5%) CoPAT patients. Clinical success rates were similar for CoPAT patients receiving daptomycin (90.0%) or standard therapy (83.0%).</p></sec><sec><title>Conclusions</title><p>With proper monitoring, stable patients can complete treatment for SAB/IE as outpatients in the community setting. Daptomycin is an appropriate option for this setting.</p></sec></abstract><sec id="s3"><title>Results</title><sec id="s3a"><title>Patient characteristics</title><p>Two hundred US patients were included in this analysis, with 103 (51.5%) receiving part of their treatment outside of the hospital setting (CoPAT). The majority of CoPAT patients (69/103, 67.0%) were discharged home without assistance and two others (1.9%) went home with assistance. Nineteen of the 103 CoPAT patients (18.4%) were discharged to a skilled nursing facility, while 13/103 (12.6%) were treated in an assisted-living setting, nursing home or rehabilitation centre. The study database did not systematically record the types of venous access devices used to deliver CoPAT. In general, peripherally inserted central catheters were the preferred means of securing venous access.</p><p>Compared with patients who received all care in the hospital, CoPAT patients were younger (median age 50 versus 54 years, <italic>P</italic> = 0.028) and tended to have fewer cases of endocardial involvement (8.7% versus 18.6%; <italic>P</italic> = 0.061) as well as less pre-existing valvular heart disease (7.8% versus 15.5%, <italic>P</italic> = 0.120). The two groups had a similar distribution of diagnoses (Figure&#x000a0;<xref ref-type="fig" rid="DKP051F1">1</xref>) and a similar distribution of study medications. Baseline demographic, diagnostic and treatment characteristics are shown in Table&#x000a0;<xref ref-type="table" rid="DKP051TB1">1</xref>.</p><table-wrap id="DKP051TB1" position="float"><label>Table&#x000a0;1</label><caption><p>Demographics, diagnosis and treatment characteristics by treatment location</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1" /><col align="char" char="." span="1" /><col align="char" char="." span="1" /><col align="char" char="." span="1" /></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">CoPAT (<italic>n</italic> = 103)</th><th align="left" rowspan="1" colspan="1">IPAT (<italic>n</italic> = 97)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic><sup>a</sup></th></tr></thead><tbody><tr><td colspan="4" rowspan="1">Study drug</td></tr><tr><td rowspan="1" colspan="1">&#x02003;daptomycin</td><td rowspan="1" colspan="1">50 (48.5%)<sup>b</sup></td><td rowspan="1" colspan="1">50 (51.5%)</td><td rowspan="1" colspan="1">0.687<sup>c</sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;vancomycin<sup>d</sup></td><td rowspan="1" colspan="1">30 (29.1%)</td><td rowspan="1" colspan="1">23 (23.7%)</td><td rowspan="1" colspan="1" /></tr><tr><td rowspan="1" colspan="1">&#x02003;SSP<sup>d</sup></td><td rowspan="1" colspan="1">23 (22.3%)</td><td rowspan="1" colspan="1">24 (24.7%)</td><td rowspan="1" colspan="1" /></tr><tr><td colspan="4" rowspan="1">Age (years)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;median</td><td rowspan="1" colspan="1">50.0</td><td rowspan="1" colspan="1">54.0</td><td rowspan="1" colspan="1">0.028<sup>e</sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;range</td><td rowspan="1" colspan="1">21&#x02013;90</td><td rowspan="1" colspan="1">24&#x02013;91</td><td rowspan="1" colspan="1" /></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">60 (58.3%)</td><td rowspan="1" colspan="1">59 (60.8%)</td><td rowspan="1" colspan="1">0.774</td></tr><tr><td colspan="4" rowspan="1">Race</td></tr><tr><td rowspan="1" colspan="1">&#x02003;white</td><td rowspan="1" colspan="1">66 (64.1%)</td><td rowspan="1" colspan="1">55 (56.7%)</td><td rowspan="1" colspan="1">0.070<sup>c</sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;black</td><td rowspan="1" colspan="1">30 (29.1%)</td><td rowspan="1" colspan="1">25 (25.8%)</td><td rowspan="1" colspan="1" /></tr><tr><td rowspan="1" colspan="1">&#x02003;other</td><td rowspan="1" colspan="1">7 (6.8%)</td><td rowspan="1" colspan="1">17 (17.5%)</td><td rowspan="1" colspan="1" /></tr><tr><td colspan="4" rowspan="1">Weight (kg)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;median</td><td rowspan="1" colspan="1">81.7</td><td rowspan="1" colspan="1">78.2</td><td rowspan="1" colspan="1">0.493<sup>e</sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;range</td><td rowspan="1" colspan="1">49.9&#x02013;129.0</td><td rowspan="1" colspan="1">53.5&#x02013;131.4</td><td rowspan="1" colspan="1" /></tr><tr><td rowspan="1" colspan="1">MRSA</td><td rowspan="1" colspan="1">37 (35.9%)</td><td rowspan="1" colspan="1">39 (40.6%)<sup>f</sup></td><td rowspan="1" colspan="1">0.560</td></tr><tr><td colspan="4" rowspan="1">CL<sub>CR</sub> (mL/min)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;median</td><td rowspan="1" colspan="1">92.1</td><td rowspan="1" colspan="1">86.0</td><td rowspan="1" colspan="1">0.064<sup>e</sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;range</td><td rowspan="1" colspan="1">29.4&#x02013;277.0</td><td rowspan="1" colspan="1">17.9&#x02013;200.8</td><td rowspan="1" colspan="1" /></tr><tr><td rowspan="1" colspan="1">CL<sub>CR</sub> &#x0003c;50 mL/min</td><td rowspan="1" colspan="1">12 (11.7%)</td><td rowspan="1" colspan="1">12 (12.4%)</td><td rowspan="1" colspan="1">&#x0003e;0.999</td></tr><tr><td rowspan="1" colspan="1">Evidence of endocardial involvement</td><td rowspan="1" colspan="1">9 (8.7%)</td><td rowspan="1" colspan="1">18 (18.6%)</td><td rowspan="1" colspan="1">0.061</td></tr><tr><td rowspan="1" colspan="1">Injection drug use</td><td rowspan="1" colspan="1">26 (25.2%)</td><td rowspan="1" colspan="1">22 (22.7%)</td><td rowspan="1" colspan="1">0.741</td></tr><tr><td rowspan="1" colspan="1">Pre-existing valvular heart disease</td><td rowspan="1" colspan="1">8 (7.8%)</td><td rowspan="1" colspan="1">15 (15.5%)</td><td rowspan="1" colspan="1">0.120</td></tr><tr><td rowspan="1" colspan="1">Fever on day 4</td><td rowspan="1" colspan="1">10 (9.7%)</td><td rowspan="1" colspan="1">18 (18.8%)<sup>g</sup></td><td rowspan="1" colspan="1">0.101</td></tr><tr><td rowspan="1" colspan="1">Completed treatment</td><td rowspan="1" colspan="1">93 (90.3%)</td><td rowspan="1" colspan="1">44 (45.4%)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td colspan="4" rowspan="1">Duration of treatment (days)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;mean (SD)</td><td rowspan="1" colspan="1">25.4 (12.34)</td><td rowspan="1" colspan="1">13.5 (9.49)</td><td rowspan="1" colspan="1">&#x0003c;0.001<sup>h</sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;range</td><td rowspan="1" colspan="1">9&#x02013;74</td><td rowspan="1" colspan="1">1&#x02013;43</td><td rowspan="1" colspan="1" /></tr><tr><td colspan="4" rowspan="1">Days inpatient during treatment</td></tr><tr><td rowspan="1" colspan="1">&#x02003;mean (SD)</td><td rowspan="1" colspan="1">10.5 (7.27)</td><td rowspan="1" colspan="1">13.5 (9.49)</td><td rowspan="1" colspan="1">0.014<sup>h</sup></td></tr><tr><td rowspan="1" colspan="1">&#x02003;range</td><td rowspan="1" colspan="1">2&#x02013;38</td><td rowspan="1" colspan="1">1&#x02013;43</td><td rowspan="1" colspan="1" /></tr><tr><td colspan="4" rowspan="1">Days outpatient during treatment</td></tr><tr><td rowspan="1" colspan="1">&#x02003;mean (SD)</td><td rowspan="1" colspan="1">14.9 (10.08)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&#x02003;range</td><td rowspan="1" colspan="1">1&#x02013;49</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1" /></tr><tr><td rowspan="1" colspan="1">Experienced &#x02265;1 SAE</td><td rowspan="1" colspan="1">48 (46.6%)</td><td rowspan="1" colspan="1">52 (53.6%)</td><td rowspan="1" colspan="1">0.396</td></tr></tbody></table><table-wrap-foot><fn><p>CoPAT, outpatient parenteral antimicrobial therapy in the community setting; IPAT, patients receiving their full course of therapy in the hospital setting; SSP, semi-synthetic penicillin; MRSA, methicillin-resistant <italic>S. aureus</italic>; NA, not applicable; SAE, serious adverse event.</p></fn><fn><p><sup>a</sup>Fisher's exact test, unless otherwise specified.</p></fn><fn><p><sup>b</sup>No. (%), unless otherwise specified.</p></fn><fn><p><sup>c</sup>Overall Fisher's exact test for characteristic.</p></fn><fn><p><sup>d</sup>With or without concomitant gentamicin.</p></fn><fn><p><sup>e</sup>Wilcoxon's rank sum test.</p></fn><fn><p><sup>f</sup><italic>n</italic> = 96 for MRSA.                         </p></fn><fn><p><sup>g</sup><italic>n</italic> = 96 for fever (inpatient): fever on day 4 was possible but not definitive on day 4 for six patients in the inpatient group who were considered to have not had a fever.                         </p></fn><fn><p><sup>h</sup><italic>t</italic>-test.                         </p></fn></table-wrap-foot></table-wrap><fig id="DKP051F1" position="float"><label>Figure&#x000a0;1</label><caption><p>Final diagnosis by CoPAT or IPAT treatment. CoPAT, outpatient parenteral antimicrobial therapy in the community setting; IPAT, patients receiving their full course of therapy in the hospital setting; uBAC, uncomplicated bacteraemia; cBAC, complicated bacteraemia; RIE, right-sided infective endocarditis; LIE, left-sided infective endocarditis.</p></caption><graphic xlink:href="dkp05101" /></fig><p>Other differences between the treatment groups included a trend towards higher baseline CL<sub>CR</sub> in the CoPAT patients (median 92.1 versus 86.0 mL/min, <italic>P</italic> = 0.064) and a trend towards a lower percentage of CoPAT patients with fever at day 4 of treatment (9.7% versus 18.8%, <italic>P</italic> = 0.101). Among CoPAT patients, baseline characteristics were similar for those receiving either daptomycin or comparator treatment (Table&#x000a0;<xref ref-type="table" rid="DKP051TB2">2</xref>).</p><table-wrap id="DKP051TB2" position="float"><label>Table&#x000a0;2</label><caption><p>Demographic, diagnosis and treatment characteristics by treatment group among CoPAT patients</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1" /><col align="char" char="." span="1" /><col align="char" char="." span="1" /></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">Daptomycin (<italic>n</italic> = 50)</th><th align="left" rowspan="1" colspan="1">Comparator<sup>a</sup> (<italic>n</italic> = 53)</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">Age (years)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;median</td><td rowspan="1" colspan="1">46.5</td><td rowspan="1" colspan="1">52.0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;range</td><td rowspan="1" colspan="1">21&#x02013;81</td><td rowspan="1" colspan="1">25&#x02013;90</td></tr><tr><td colspan="3" rowspan="1">Gender</td></tr><tr><td rowspan="1" colspan="1">&#x02003;male</td><td rowspan="1" colspan="1">31 (62.0%)<sup>b</sup></td><td rowspan="1" colspan="1">29 (54.7%)</td></tr><tr><td colspan="3" rowspan="1">Race</td></tr><tr><td rowspan="1" colspan="1">&#x02003;white</td><td rowspan="1" colspan="1">26 (52.0%)</td><td rowspan="1" colspan="1">40 (75.5%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;black</td><td rowspan="1" colspan="1">19 (38.0%)</td><td rowspan="1" colspan="1">11 (20.8%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;other</td><td rowspan="1" colspan="1">5 (10.0%)</td><td rowspan="1" colspan="1">2 (3.8%)</td></tr><tr><td colspan="3" rowspan="1">Weight (kg)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;median</td><td rowspan="1" colspan="1">82.1</td><td rowspan="1" colspan="1">80.0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;range</td><td rowspan="1" colspan="1">55.0&#x02013;129.0</td><td rowspan="1" colspan="1">49.9&#x02013;124.8</td></tr><tr><td rowspan="1" colspan="1">MRSA</td><td rowspan="1" colspan="1">18 (36.0%)</td><td rowspan="1" colspan="1">19 (35.8%)</td></tr><tr><td colspan="3" rowspan="1">CL<sub>CR</sub> (mL/min)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;median</td><td rowspan="1" colspan="1">108.1</td><td rowspan="1" colspan="1">86.4</td></tr><tr><td rowspan="1" colspan="1">&#x02003;range</td><td rowspan="1" colspan="1">29.4&#x02013;246.9</td><td rowspan="1" colspan="1">31.0&#x02013;277.0</td></tr><tr><td rowspan="1" colspan="1">CL<sub>CR</sub> &#x0003c;50 mL/min</td><td rowspan="1" colspan="1">4 (8.0%)</td><td rowspan="1" colspan="1">8 (15.1%)</td></tr><tr><td rowspan="1" colspan="1">Evidence of endocardial involvement</td><td rowspan="1" colspan="1">4 (8.0%)</td><td rowspan="1" colspan="1">5 (9.4%)</td></tr><tr><td rowspan="1" colspan="1">Injection drug use</td><td rowspan="1" colspan="1">14 (28.0%)</td><td rowspan="1" colspan="1">12 (22.6%)</td></tr><tr><td rowspan="1" colspan="1">Pre-existing valvular heart disease</td><td rowspan="1" colspan="1">3 (6.0%)</td><td rowspan="1" colspan="1">5 (9.4%)</td></tr><tr><td rowspan="1" colspan="1">Fever on day 4</td><td rowspan="1" colspan="1">3 (6.0%)</td><td rowspan="1" colspan="1">7 (13.2%)</td></tr><tr><td rowspan="1" colspan="1">Completed treatment</td><td rowspan="1" colspan="1">46 (92.0%)</td><td rowspan="1" colspan="1">47 (88.7%)</td></tr><tr><td colspan="3" rowspan="1">Duration of treatment (days)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;mean (SD)</td><td rowspan="1" colspan="1">25.9 (13.31)</td><td rowspan="1" colspan="1">25.0 (11.46)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;range</td><td rowspan="1" colspan="1">11&#x02013;74</td><td rowspan="1" colspan="1">9&#x02013;57</td></tr><tr><td colspan="3" rowspan="1">Days inpatient during treatment</td></tr><tr><td rowspan="1" colspan="1">&#x02003;mean (SD)</td><td rowspan="1" colspan="1">10.7 (7.06)</td><td rowspan="1" colspan="1">10.3 (7.52)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;range</td><td rowspan="1" colspan="1">5&#x02013;38</td><td rowspan="1" colspan="1">2&#x02013;35</td></tr><tr><td colspan="3" rowspan="1">Days outpatient during treatment</td></tr><tr><td rowspan="1" colspan="1">&#x02003;mean (SD)</td><td rowspan="1" colspan="1">15.2 (10.08)</td><td rowspan="1" colspan="1">14.7 (10.18)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;range</td><td rowspan="1" colspan="1">2&#x02013;46</td><td rowspan="1" colspan="1">1&#x02013;49</td></tr><tr><td colspan="3" rowspan="1">Final diagnosis</td></tr><tr><td rowspan="1" colspan="1">&#x02003;uBAC</td><td rowspan="1" colspan="1">10 (20.0%)</td><td rowspan="1" colspan="1">17 (32.1%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;cBAC</td><td rowspan="1" colspan="1">27 (54.0%)</td><td rowspan="1" colspan="1">24 (45.3%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;RIE</td><td rowspan="1" colspan="1">11 (22.0%)</td><td rowspan="1" colspan="1">8 (15.1%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;LIE</td><td rowspan="1" colspan="1">2 (4.0%)</td><td rowspan="1" colspan="1">4 (7.5%)</td></tr><tr><td rowspan="1" colspan="1">Experienced &#x02265;1 SAE</td><td rowspan="1" colspan="1">23 (46.0%)</td><td rowspan="1" colspan="1">25 (47.2%)</td></tr></tbody></table><table-wrap-foot><fn><p>CoPAT, outpatient parenteral antimicrobial therapy in the community setting; MRSA, methicillin-resistant <italic>S. aureus</italic>; uBAC, uncomplicated bacteraemia; cBAC, complicated bacteraemia; RIE, right-sided infective endocarditis; LIE, left-sided infective endocarditis; SAE, serious adverse event.</p></fn><fn><p><sup>a</sup>Comparator treatment was semi-synthetic penicillin/gentamicin or vancomycin/gentamicin.</p></fn><fn><p><sup>b</sup>No. (%), unless otherwise specified.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Patient outcomes</title><p>Among CoPAT patients, clinical success rates were similar regardless of study medication, with 45/50 (90.0%) daptomycin patients and 44/53 (83.0%) comparator patients experiencing clinical success. For IPAT patients, clinical success was observed in 26/50 (52.0%) daptomycin patients and 28/47 (59.6%) comparator patients. Thus, it is justified to combine the treatment groups for analysis of outcomes.</p><p>CoPAT patients received longer courses of study antibiotics with a mean of 25.4 days (range 9&#x02013;74 days) compared with 13.5 days (range 1&#x02013;43) in the IPAT group (<italic>P</italic> &#x0003c; 0.001), and a higher proportion of CoPAT patients completed therapy as part of the study (90.3% versus 45.4%, <italic>P</italic> &#x0003c; 0.001). CoPAT patients received a mean of 14.9 days of therapy outside the hospital setting (Table&#x000a0;<xref ref-type="table" rid="DKP051TB1">1</xref>). The shorter duration of study treatment for IPAT patients was influenced by early discontinuations: there were 53 (54.6%) versus 10 (9.7%) in the CoPAT group. The most common reason for discontinuation was adverse events, which accounted for 25/53 (47.2%) IPAT and 8/10 (80.0%) CoPAT patient discontinuations. The adverse events responsible for discontinuation, including rash, infection, renal failure and creatine phosphokinase elevation, are listed in Table&#x000a0;<xref ref-type="table" rid="DKP051TB3">3</xref>. IPAT patients whose study participation was terminated prior to the end of therapy received subsequent antibiotic therapy as appropriate, but specific information regarding types and duration of additional therapy was not part of the study database.</p><table-wrap id="DKP051TB3" position="float"><label>Table&#x000a0;3</label><caption><p>Adverse events leading to discontinuation</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1" /><col align="char" char="." span="1" /><col align="char" char="." span="1" /></colgroup><thead><tr><th rowspan="1" colspan="1" /><th align="left" rowspan="1" colspan="1">CoPAT (<italic>n</italic> = 8)<sup>a</sup></th><th align="left" rowspan="1" colspan="1">IPAT (<italic>n</italic> = 25)<sup>a</sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Anaphylactic reaction</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Skin<sup>b</sup></td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">Red man syndrome</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Diabetic gastroparesis</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Vomiting not otherwise specified</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Blood creatine phosphokinase increased</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Cardiovascular<sup>c</sup></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">Hypoxia</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Infection<sup>d</sup></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Fever</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Renal failure</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">Sepsis</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1">Thrombocytopenia</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup>Number of discontinuations due to an adverse event.</p></fn><fn><p><sup>b</sup>Skin includes dermatitis bullous, dermatitis medicamentosa, erythematous rash, vesicular rash and rash not otherwise specified.</p></fn><fn><p><sup>c</sup>Cardiovascular includes cardiac arrest (two patients), cerebrovascular accident and circulatory collapse.</p></fn><fn><p><sup>d</sup>Infection includes osteomyelitis not otherwise specified, staphylococcal pneumonia and staphylococcal bacteraemia.</p></fn></table-wrap-foot></table-wrap><p>A higher rate of clinical success at the test-of-cure visit was observed among CoPAT patients (89/103, 86.4%) compared with that among IPAT patients (54/97, 55.7%) (<italic>P</italic> &#x0003c; 0.001). Four of the 103 CoPAT patients (3.9%) experienced persisting or relapsing <italic>S</italic>. <italic>aureus</italic> infection, compared with 15/97 IPAT patients (15.5%, <italic>P</italic> = 0.007). Fewer deaths occurred in the CoPAT group (4/103, 3.9%) compared with those in the IPAT group (18/97, 18.6%; <italic>P</italic> = 0.001) (Table&#x000a0;<xref ref-type="table" rid="DKP051TB4">4</xref>).</p><table-wrap id="DKP051TB4" position="float"><label>Table&#x000a0;4</label><caption><p>Clinical outcomes for CoPAT patients versus IPAT patients</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1" /><col align="char" char="(" span="1" /><col align="char" char="(" span="1" /><col align="char" char="." span="1" /></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Clinical outcome 6 weeks after end of therapy</th><th align="left" rowspan="1" colspan="1">CoPAT<sup>a</sup> (<italic>n</italic> = 103)</th><th align="left" rowspan="1" colspan="1">IPAT (<italic>n</italic> = 97)</th><th align="left" rowspan="1" colspan="1"><italic>P</italic><sup>b</sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Clinical success</td><td rowspan="1" colspan="1">89 (86.4%)<sup>c</sup></td><td rowspan="1" colspan="1">54 (55.7%)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Failure</td><td rowspan="1" colspan="1">10 (9.7%)</td><td rowspan="1" colspan="1">26 (26.8%)</td><td rowspan="1" colspan="1" /></tr><tr><td rowspan="1" colspan="1">Non-evaluable</td><td rowspan="1" colspan="1">4 (3.9%)</td><td rowspan="1" colspan="1">17 (17.5%)</td><td rowspan="1" colspan="1" /></tr><tr><td rowspan="1" colspan="1">Death</td><td rowspan="1" colspan="1">4 (3.9%)</td><td rowspan="1" colspan="1">18 (18.6%)</td><td rowspan="1" colspan="1">0.001</td></tr></tbody></table><table-wrap-foot><fn><p>CoPAT, outpatient parenteral antimicrobial therapy in the community setting; IPAT, patients receiving their full course of therapy in the hospital setting.</p></fn><fn><p><sup>a</sup>Inpatients who were partly treated outside a hospital.</p></fn><fn><p><sup>b</sup>Fisher's exact test.</p></fn><fn><p><sup>c</sup>No. (%).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Escalation of care</title><p>Twice as many CoPAT patients (22/103, 21.4%) were transferred to a higher level of care during their course of treatment compared with those transferred among IPAT patients (10/97, 10.3%), a difference that reached statistical significance (<italic>P</italic> = 0.036) (Table&#x000a0;<xref ref-type="table" rid="DKP051TB5">5</xref>). Hospital readmission was required for 18 of the 103 (17.5%) CoPAT patients. As shown in Table&#x000a0;<xref ref-type="table" rid="DKP051TB6">6</xref>, the reasons for hospital readmission were diverse. Four patients (22.2% of the readmissions and 3.9% of CoPAT patients) were readmitted for reasons related to their initial infection, including osteomyelitis or relapsed SAB. Problems related to provision of treatment in the post-acute care setting led to the readmission of three patients, two of whom relapsed with iv drug use (IVDU) and one of whom developed <italic>Clostridium difficile</italic> colitis. Other medical conditions leading to readmission included pneumonia in three patients and a myriad of other conditions, including unknown reasons, which were each experienced by a single patient. Of the 18 CoPAT patients readmitted to the hospital during the study, half subsequently returned to treatment in the CoPAT setting.</p><table-wrap id="DKP051TB5" position="float"><label>Table&#x000a0;5</label><caption><p>Escalation of care and patient location at last dose of study drug</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1" /><col align="char" char="(" span="1" /><col align="char" char="(" span="1" /></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">CoPAT (<italic>n</italic> = 103)</th><th align="left" rowspan="1" colspan="1">IPAT (<italic>n</italic> = 97)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Transferred to higher level of care at any time during treatment</td><td rowspan="1" colspan="1">22 (21.4%)<sup>a&#x02013;c</sup></td><td rowspan="1" colspan="1">10 (10.3%)</td></tr><tr><td colspan="3" rowspan="1">No. times readmitted to hospital to complete treatment with study drug</td></tr><tr><td rowspan="1" colspan="1">&#x02003;one</td><td rowspan="1" colspan="1">17 (16.5%)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&#x02003;two</td><td rowspan="1" colspan="1">1 (1.0%)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">Returned to outpatient care after readmission</td><td rowspan="1" colspan="1">9 (50.0%)<sup>d</sup></td><td rowspan="1" colspan="1">NA</td></tr><tr><td colspan="3" rowspan="1">Reasons readmitted</td></tr><tr><td rowspan="1" colspan="1">&#x02003;factors relating to initial infection</td><td rowspan="1" colspan="1">4 (22.2%)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&#x02003;other conditions<sup>e</sup></td><td rowspan="1" colspan="1">11 (61.1%)</td><td rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="1" colspan="1">&#x02003;issues relating to provision of treatment at home</td><td rowspan="1" colspan="1">3 (16.7%)<sup>f</sup></td><td rowspan="1" colspan="1">NA</td></tr><tr><td colspan="3" rowspan="1">Location for last dose of study drug</td></tr><tr><td rowspan="1" colspan="1">&#x02003;for patients who completed treatment</td><td rowspan="1" colspan="1">93 (90.3%)</td><td rowspan="1" colspan="1">44 (45.4%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;in hospital setting</td><td rowspan="1" colspan="1">8 (7.8%)<sup>g</sup></td><td rowspan="1" colspan="1">44 (45.4%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;as an outpatient</td><td rowspan="1" colspan="1">85 (82.5%)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">&#x02003;for patients who prematurely discontinued treatment</td><td rowspan="1" colspan="1">10 (9.7%)</td><td rowspan="1" colspan="1">53 (54.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;in hospital setting</td><td rowspan="1" colspan="1">2 (1.9%)<sup>g</sup></td><td rowspan="1" colspan="1">53 (54.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02003;as an outpatient</td><td rowspan="1" colspan="1">8 (7.8%)</td><td rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn><p>CoPAT, outpatient parenteral antimicrobial therapy in the community setting; IPAT, patients receiving their full course of therapy in the hospital setting; NA, not applicable.</p></fn><fn><p><sup>a</sup>No. (%).</p></fn><fn><p><sup>b</sup><italic>P</italic> = 0.036, Fisher's exact test.                     </p></fn><fn><p><sup>c</sup>One patient had increased level of care within post-acute care but was not readmitted to hospital. Three patients had escalation of inpatient care prior to post-acute care.</p></fn><fn><p><sup>d</sup>Based on the 18 patients who were readmitted to hospital.</p></fn><fn><p><sup>e</sup>Underlying disease or new problems not related to the initial infection. See Table&#x000a0;<xref ref-type="table" rid="DKP051TB6">6</xref>.</p></fn><fn><p><sup>f</sup>One patient was readmitted twice for the same problem related to delivery of treatment at home. See Table&#x000a0;<xref ref-type="table" rid="DKP051TB6">6</xref>.</p></fn><fn><p><sup>g</sup>Patients readmitted to hospital.</p></fn></table-wrap-foot></table-wrap><table-wrap id="DKP051TB6" position="float"><label>Table&#x000a0;6</label><caption><p>Patient status and factors related to hospital readmission among CoPAT patients</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1" /><col align="char" char="/" span="1" /></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">CoPAT patients (<italic>n</italic> = 103)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">No. of post-acute care patients readmitted<sup>a</sup></td><td rowspan="1" colspan="1">18/103 (17.5%)<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">Reasons for readmission</td><td rowspan="1" colspan="1" /></tr><tr><td colspan="2" rowspan="1">Factors relating to initial infection (<italic>n</italic> = 4)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;osteomyelitis</td><td rowspan="1" colspan="1">2/18 (11.1%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;relapsed <italic>S. aureus</italic> bacteraemia</td><td rowspan="1" colspan="1">1/18 (5.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;embolic stroke</td><td rowspan="1" colspan="1">1/18 (5.6%)</td></tr><tr><td colspan="2" rowspan="1">Other conditions (<italic>n</italic> = 11)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;pneumonia</td><td rowspan="1" colspan="1">3/18 (16.7%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;urinary tract infection</td><td rowspan="1" colspan="1">1/18 (5.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;fever of unknown origin</td><td rowspan="1" colspan="1">1/18 (5.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;gout</td><td rowspan="1" colspan="1">1/18 (5.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;seizures (history of seizure disorder)</td><td rowspan="1" colspan="1">1/18 (5.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;sarcoid</td><td rowspan="1" colspan="1">1/18 (5.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;gastroparesis</td><td rowspan="1" colspan="1">1/18 (5.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;left against medical advice</td><td rowspan="1" colspan="1">1/18 (5.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;unknown</td><td rowspan="1" colspan="1">1/18 (5.6%)</td></tr><tr><td colspan="2" rowspan="1">Issues relating to receipt of treatment at home (<italic>n</italic> = 3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;drug use</td><td rowspan="1" colspan="1">2/18 (11.1%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;<italic>C. difficile</italic> colitis</td><td rowspan="1" colspan="1">1/18 (5.6%)</td></tr><tr><td colspan="2" rowspan="1">Study drug</td></tr><tr><td rowspan="1" colspan="1">&#x02003;daptomycin</td><td rowspan="1" colspan="1">9/50 (18.0%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;vancomycin</td><td rowspan="1" colspan="1">4/30 (13.3%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;semi-synthetic penicillin</td><td rowspan="1" colspan="1">5/23 (21.7%)</td></tr><tr><td colspan="2" rowspan="1">Final diagnosis</td></tr><tr><td rowspan="1" colspan="1">&#x02003;uBAC</td><td rowspan="1" colspan="1">2/27 (7.4%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;cBAC</td><td rowspan="1" colspan="1">10/51 (19.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;RIE</td><td rowspan="1" colspan="1">6/19 (31.6%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;LIE</td><td rowspan="1" colspan="1">0/6</td></tr><tr><td colspan="2" rowspan="1">Intravenous drug user</td></tr><tr><td rowspan="1" colspan="1">&#x02003;no</td><td rowspan="1" colspan="1">11/77 (14.3%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;yes</td><td rowspan="1" colspan="1">7/26 (26.9%)</td></tr></tbody></table><table-wrap-foot><fn><p>CoPAT, outpatient parenteral antimicrobial therapy in the community setting; uBAC, uncomplicated bacteraemia; cBAC, complicated bacteraemia; RIE, right-sided infective endocarditis; LIE, left-sided infective endocarditis.</p></fn><fn><p><sup>a</sup>One patient was readmitted twice for reasons relating to treatment at home.</p></fn><fn><p><sup>b</sup>No. (%).</p></fn></table-wrap-foot></table-wrap><p>IVDU was associated with an increased risk of hospital readmission for CoPAT patients, with 7/26 (26.9%) IVDU patients requiring readmission, compared with 11/77 (14.3%) non-IVDU patients requiring readmission. The use of iv drugs during therapy was documented in two of the seven readmitted IVDU patients. Also of note was the fact that a higher proportion of patients with right-sided IE (6/19, 31.6%), though not statistically significant, required hospital readmission compared with those with other final diagnoses (Table&#x000a0;<xref ref-type="table" rid="DKP051TB6">6</xref>). Five of the six readmitted patients with right-sided IE were iv drug users (four complicated right-sided IE and one uncomplicated right-sided IE).</p></sec></sec>